Sequana Medical NV (Sequana Medical NV) Debt-to-Asset : 0.70 (As of Jun. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Sequana Medical NV Debt-to-Asset?

Sequana Medical NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $3.43 Mil. Sequana Medical NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $15.69 Mil. Sequana Medical NV's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was $27.22 Mil. Sequana Medical NV's debt to asset for the quarter that ended in Jun. 2023 was 0.70.

Sequana Medical NV Debt-to-Asset Historical Data

The historical data trend for Sequana Medical NV's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sequana Medical NV Debt-to-Asset Chart

Sequana Medical NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

4.39

0.35

0.55

0.68

Sequana Medical NV Quarterly Data
	Dec15	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Asset	Get a 7-Day Free Trial									0.29	0.55	0.28	0.68	0.70

Competitive Comparison of Sequana Medical NV's Debt-to-Asset

For the Medical Devices subindustry, Sequana Medical NV's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sequana Medical NV's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sequana Medical NV's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sequana Medical NV's Debt-to-Asset falls into.

Sequana Medical NV Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sequana Medical NV's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5.074	+	13.561)	/	27.569
	=	0.68

Sequana Medical NV's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.426	+	15.69)	/	27.223
	=	0.70

Sequana Medical NV (GREY:SQNMF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Sequana Medical NV Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Sequana Medical NV's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sequana Medical NV (Sequana Medical NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sequana Medical NV (GREY:SQNMF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

2SE:Germany SEQUA:Belgium

Address

Kortrijksesteenweg 1112 ,bus 102, Sint-Denijs-Westrem, Ghent, BEL, 9051

Website

https://www.sequanamedical.com

Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies and over 750 implants. The company's geographical segments include Switzerland, Germany, the United Kingdom, and the Rest of the world, out of which Germany accounts for the majority of the revenue.

Sequana Medical NV (Sequana Medical NV) Headlines

No Headlines